US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Mark Brosius, Senior Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc . (NASDAQ:ISRG), a $192 billion medical technology leader that has delivered an impressive 46% return over the past year, has recently sold shares of the company in a series of transactions. According to InvestingPro analysis, the company maintains excellent financial health with a "GREAT" overall score. According to a filing with the Securities and Exchange Commission, Brosius sold a total of 1,476 shares over three days, from March 4 to March 6, 2025. The shares were sold at prices ranging from $554.17 to $563.69, amounting to a total value of $824,990. The current valuation metrics suggest the stock is trading above its Fair Value, with InvestingPro data showing high earnings and EBITDA multiples.
Following these transactions, Brosius now holds 2,580 shares directly. The sales were executed as part of a pre-arranged trading plan under SEC Rule 10b5-1, which allows company insiders to sell a predetermined number of shares at a predetermined time. This plan is set to expire on June 13, 2025. For deeper insights into Intuitive Surgical’s valuation and financial metrics, including 14 additional exclusive ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Intuitive Surgical has reported a strong finish to its fourth quarter of 2024, surpassing expectations with a 10% and 24% beat on revenue and earnings per share (EPS), respectively. The company also reported a year-over-year EPS increase of 38% to $2.21, which exceeded consensus estimates by 22%. Intuitive Surgical’s procedure volume grew by 18% year-over-year, with a significant increase in the average selling price of its systems, driven by a higher mix of its advanced da Vinci (EPA:SGEF) 5 (dV5) systems. The company has projected a 13-16% increase in procedure volume for 2025, and analysts from RBC and Piper Sandler have maintained positive ratings, with price targets of $641 and $670, respectively.
Intuitive Surgical’s gross margin guidance for 2025 is set at 67-68%, slightly below some analyst estimates, but Piper Sandler expects margins to return to over 70% in the mid-term. Bernstein analysts have set a price target of $700, citing the company’s strong financial performance and potential for future growth. Truist Securities has increased its price target to $666, maintaining a Buy rating, and expects Intuitive Surgical to sustain a mid-to-high-teens revenue and profit growth rate over the next few years.
Despite positive developments, Oppenheimer has maintained a Perform rating, expressing concerns about market saturation in the U.S. and the pricing of the new dV5 system. Nonetheless, Intuitive Surgical’s upcoming mid-year launch of the dV5 system is anticipated to be a key driver for growth, with several analysts suggesting the company’s guidance is conservative and likely to be exceeded. The company’s recent distribution agreement in Europe and approvals for new medical indications further bolster its growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.